While Belviq leads, generic Xenical outnumbers the original
The impact of ‘Belviq’ was significant in the obesity treatment market. Ildong Pharmaceuticals’ Belviq(lorcaserin), which was first launched on March last year, recorded approximately KRW 14 billion sales in 10 months, continuing its flying performance and becoming a leading product in no time. ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
